1.
|
Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 40 to 70 Sponsor: NIGMS Protocol IDs: 0412-14, UO1-GM61373-06, NCT00228956
|
|
2.
|
Phase: Phase IV Type: Treatment Status: Active Age: 50 and over Sponsor: Other Protocol IDs: S07-002, 1098558, NCT00882596
|
|
3.
|
Phase: Phase IV Type: Treatment Status: Active Age: 45 and over Sponsor: Other Protocol IDs: Mammosite ML, NCT01448447
|
|
4.
|
Phase: Phase IV Type: Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: P0334, NCT01501487
|
|
5.
|
Phase: Phase IV Type: Treatment Status: Active Age: 40 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTPR-0009, NCT01644669
|
|
6.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Diagnostic, Treatment Status: Active Age: 19 and over Sponsor: NCI, Other Protocol IDs: 10-0366-04, NCI-2011-00710, NCT01391689
|
|
7.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000409590, NSABP-B-39, RTOG-0413, SWOG-NSABP-B-39, NCT00103181
|
|
8.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00702, NSABP-B-43, CDR0000615085, U10CA012027, NCT00769379
|
|
9.
|
Phase: Phase III Type: Treatment Status: Active Age: 40 and over Sponsor: Other Protocol IDs: 2009-APBI, WIRB #20091193, NCT01185132
|
|
10.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: RTOG 1005, NCI-2011-02669, CDR0000700069, NCT01349322
|
|
11.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: S12-01299, NCT01591811
|
|
12.
|
Phase: Phase II, Phase I Type: Diagnostic, Treatment Status: Active Age: 18 to 90 Sponsor: Other Protocol IDs: UAMS 07050, NIH Grant 5 R21 CA097715-01, NCT00574301
|
|
13.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000644921, UPCC-15107, 807010, NCT00923143
|
|
14.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Adult Sponsor: Other Protocol IDs: 2008NTLS083, UMN-0809M45461, UMN-2008NTLS083, NCT01009437
|
|
15.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: IFHCC 09-002, NCT01023477
|
|
16.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 41 and over Sponsor: Other Protocol IDs: 12-001 Single Fraction IORT, NCT01688388
|
|
17.
|
Phase: Phase II Type: Treatment Status: Active Age: 30 and over Sponsor: Other Protocol IDs: 0601000957, NCT00611624
|
|
18.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: DCIS-WHM-703M, NCT00669747
|
|
19.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 040807, CDR0000643276, CINJ-040807, NCT00909909
|
|
20.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: J0822, NCT00982319
|
|
21.
|
Phase: Phase II Type: Treatment Status: Active Age: 50 and over Sponsor: Other Protocol IDs: 040902, CDR0000660027, S09-001, CINJ-040902, NCT01019720
|
|
22.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000666991, RTOG-1014, NCT01082211
|
|
23.
|
Phase: Phase II Type: Treatment Status: Active Age: 50 and over Sponsor: Pharmaceutical / Industry Protocol IDs: S09-001, NCT01072838
|
|
24.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000675211, P30CA022453, WSU-2010-056, 2010-056, NCT01147016
|
|
25.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: J1022, SKCCC J1022, NCT01194440
|